Healthtech Klivo Raises $8M to Treat Chronic Illnesses

This Brazilian startup seeks relevant efficiency gains betting on prevention, personalized monitoring and better use of infrastructure

Bloomberg Línea — Klivo, a healthtech firm that offers solutions in the treatment of chronic illnesses such as diabetes, raised R$ 45 million ($8 million) in a Series A round led by Valor Capital.

The startup provides specialized clinical monitoring services for chronic diseases such as diabetes, hypertension, high cholesterol and obesity --the ones called non-communicable chronic diseases (NCDs) -- for health plans and health insurances, in addition to pharmaceutical companies and laboratories. These are illnesses that require constant monitoring, which usually entails medical costs, but which can also present relevant efficiency gains with a focus on prevention, personalized monitoring technology and better use of infrastructure.

Read more: Chiper closes $53M Series B, builds e-commerce for corner stores

“The healthcare system is designed for the acute event, while the chronic patient needs continuous monitoring. We came to fill this gap in the industry”, explains André Sa, one of the founders of Klivo. The company was founded in 2019 by Sa, former partner of BTG Pactual and Stone, and Marcelo Toledo, former employee at Nubank.

According to Klivo, the money will be allocated to growth, expansion of business lines and acquisitions.

In addition to Valor Capital, the following also took part in the round: Civilization Ventures, seed investor of the American Omada, which also works with chronic diseases in the U.S.; Tau Ventures, specialized in healthtech in Silicon Valley; Reaction, the Stanford University student impact fund; and Canary and Norte Ventures and some angel investors from Brazil who were already involved since the seed round in 2020.

The healthtech has a multidisciplinary health team composed of physicians, nurses, nutritionists, psychologists and physical educators, in addition to technology and devices that send data for continuous monitoring of patients 24/7. With this, the company achieves greater patient engagement in the treatment, which is capable of increasing considerably the chances of clinical improvement and reducing the final medical cost by as much as 65%. Altogether, Klivo serves 21,000 people.

Read more: Inflation Is Raging Everywhere, But It’s Worst in Latin America

In André Sa’s assessment, the pandemic anticipated several trends in the healthcare sector, increasing the need to monitor chronic patients who use medical infrastructure more frequently. “The potential is huge as 52% of Brazilians over 18 were diagnosed with at least one chronic illness in 2019. We are here to simplify and improve the health sector with the humane and intelligent use of technology, delivering better quality of life, clinical improvement and cost reduction”, explains Sa.